18th week of 2015 patent applcation highlights part 46 |
Patent application number | Title | Published |
20150118195 | Electro-Mechanically Stretched Micro Fibers and Methods of Use Thereof - The presently disclosed subject matter provides a scalable and electrostretching approach for generating microfibers exhibiting uniaxial alignment from polymer solutions. Such microfibers can be generated from a variety of natural polymers or synthetic polymers. The hydrogel microfibers can be used for controlled release of bioactive agents. The internal uniaxial alignment exhibited by the presently disclosed fibers provides improved mechanical properties to microfibers, contact guidance cues and induces alignment for cells seeded on or within the microfibers. | 2015-04-30 |
20150118196 | TREHALOSE-CONTAINING MAMMALIAN CELL SUSPENSION FOR PREVENTION OF PULMONARY EMBOLISM FORMATION - A mammalian cell suspension prevents pulmonary embolism formation during administration of mammalian cells, such as mammalian stem cells, through a blood vessel, and a preventive agent against pulmonary embolism formation during administration of mammalian cells through a blood vessel. suspending mammalian cells, such as mammalian stem cells, are suspended in a physiological aqueous solution containing trehalose or its derivative, or a salt thereof as an active ingredient to prepare a mammalian cell suspension for preventing pulmonary embolism formation during administration of the mammalian cells through a blood vessel, including the mammalian cells and trehalose or its derivative, or a salt thereof as active ingredients. Examples of the mammalian cells can include pancreatic islet cells, dendritic cells, natural killer cells, alpha/beta T cells, gamma/delta T cells, and cytotoxic T lymphocytes in addition to mammalian stem cells. Preferred mammalian stem cells can include mammalian mesenchymal stem cells and mammalian pluripotent stem cells. | 2015-04-30 |
20150118197 | SCAFFOLD - The invention provides a method for producing an electrospun scaffold, comprising electrospinning a polymer or co-polymer onto a template comprising a conductive collector having a three dimensional pattern thereon, wherein said electrospun polymer or co-polymer preferentially deposits onto said three dimensional pattern. | 2015-04-30 |
20150118198 | BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AS A SOURCE OF NEURAL PROGENITORS - Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types. | 2015-04-30 |
20150118199 | METHODS OF MEASURING POTENTIAL FOR THERAPEUTIC POTENCY AND DEFINING DOSAGES FOR AUTOLOGOUS CELL THERAPIES - Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (BMC) from the patient for the phenotypic profile, such as a CD profile, the phenotype profile may be assessed to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC. | 2015-04-30 |
20150118200 | PRODUCTION OF EXTRACELLULAR MATRIX, CONDITIONED MEDIA AND USES THEREOF - Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided. Also provided are conditioned media, related compositions, related methods, and related packaging products. | 2015-04-30 |
20150118201 | Directed Evolution and In Vitro Panning of Virus Vectors - The present invention provides methods of achieving directed evolution of viruses by in vivo screening or “panning” to identify viruses comprising scrambled AAV capsids having characteristics of interest, e.g., tropism profile and/or neutralization profile (e.g., ability to evade neutralizing antibodies). The invention also provides scrambled AAV capsids and virus particles comprising the same. | 2015-04-30 |
20150118202 | Methods for Treatment of Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain | 2015-04-30 |
20150118203 | Delivery System and Probiotic Composition for Animals and Plants - Probiotic compositions that comprise one or more bacteria species in spore form, a thickener to form a stabilized suspension and to preferably act as a prebiotic, one or more acids or salts of acids, and optionally a water activity reducer. A system for delivering probiotic compositions by gravity feed or non-contact pump to a point of consumption by a plant or animal, preferably in conjunction with acidified drinking water, comprising a collapsible container with attachable tubing that prevent contamination of the probiotic composition within the container. Delivery may be actuated in response to a timer, motion detector, fluid level sensor, RFID tag, or other mechanism to periodically or continuously dispense a dosage of probiotic composition directly to the soil surrounding a plant or to the water or feed for an animal. A method for increasing beneficial bacteria in an animal's GIT comprises adding probiotics to acidified drinking water. | 2015-04-30 |
20150118204 | BACTERIAL COMPOSITION - A bacterial composition that inhibits | 2015-04-30 |
20150118205 | EFFECTIVE CONTROL OF VIRAL PLANT DISEASE WITH STRAINS OF PSEUDOMONAS OLEOVORANS - A strain of | 2015-04-30 |
20150118206 | STROMAL CELL THERAPY IN TREATMENT OF RADIATION INJURY - Methods are provided for treating, mitigating or protecting from radiation-induced injury using bone marrow stromal cells expanded in culture, adipose-tissue derived non-adherent stromal cells, or the culture supernatant thereof. | 2015-04-30 |
20150118207 | METHOD FOR PRODUCING NATURAL KILLER CELLS, NATURAL KILLER CELLS PRODUCED THEREBY, AND COMPOSITION FOR TREATING CANCERS AND INFECTIOUS DISEASES CONTAINING THE SAME - The present invention relates to a method for producing natural killer cells (hereinafter, referred to as “NK cells”), NK cells produced thereby, and a composition for treating cancers and infectious diseases containing the same. The present invention provides a method for producing NK cells, which maintain high cytotoxicity and cell viability to exhibit high therapeutic effects against cancers and infectious diseases and can be cultured ex vivo at high efficiency and high concentration. In addition, a culture method which maintains cell concentration at a constant level is used for the production of NK cells, and thus the overgrowth of the cells can be prevented so that the cells can be maintained at an optimal state. Particularly, even when the cells are thawed after freezing, the function of the cells is not impaired, and the NK cells can maintain high cell viability and cytotoxicity. Thus, the NK cells can be easily stored and supplied in a liquid or frozen state without needing an additional treatment process. | 2015-04-30 |
20150118208 | ENHANCED AFFINITY T CELL RECEPTORS AND METHODS FOR MAKING THE SAME - The present disclosure provides methods for generating enhanced affinity T cell receptors by agonist selection of hematopoietic progenitor cells expressing an antigen specific TCRα cultured with stromal cells expressing Delta-like-1 or Delta-like-4, compositions prepared from such methods, and uses of thereof. | 2015-04-30 |
20150118209 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE - Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease. | 2015-04-30 |
20150118210 | COMPOSITION FOR ENHANCING CELL ENGRAFTMENT AND HOMING PROPERTIES CONTAINING PRP AS ACTIVE INGREDIENT - The present invention provides a composition for enhancing cell engraftment and homing properties, containing platelet-rich plasma (PRP) as an active ingredient. The present invention provides a method for improving cell engraftment and homing properties, comprising the step of treating in vitro isolated cells with a composition containing PRP as an active ingredient. According to the present invention, when a cell to be transplanted or a region to which cells are transplanted is treated with PRP, or a cell to be transplanted is mixed with PRP, transplantation to an in vivo region is carried out, thereby increasing cell engraftment in a transplanted region and increasing cell homing from a transplanted region to a damaged region. | 2015-04-30 |
20150118211 | Enzymatic Prevention and Control of Biofilm - The invention provides methods, compositions, and kits for removal of biofilms from surfaces. The methods described herein comprise simultaneous or sequential application of a perhydrolase enzyme and a mixture of other enzymes, such as proteases, glucanases, esterases, mannanases, phospholipases, cellulases, and/or amylases, to a biofilm on a surface, to effect removal of the biofilm. | 2015-04-30 |
20150118212 | MUTANTS OF STAPHYLOKINASE CARRYING AMINO AND CARBOXY-TERMINAL EXTENSIONS FOR POLYETHYLENE GLYCOL CONJUGATION - The present invention relates to the development of new derivatives of a bacterial plasminogen activator, Staphylokinase (SAK), having one or more amino acid residues with single or multiple cysteines at the amino and/or carboxy terminal ends and their conjugation with PEG (Polyethylene Glycol), resulting in new Staphylokinase derivatives that display altered oligomeric states, enhanced thermal and protease stability and extended plasma half-life. Also included is the cloning and expression in a suitable bacterial host; purification of Staphylokinase derivatives to homogeneity and their chemical modification by integrating a PEG molecule to create new biologically active Staphylokinases having higher protein stability and improved in vivo plasma half life, that may enhance the clinical potential of Staphylokinase in thrombolytic therapy for the treatment of cardiovascular diseases. | 2015-04-30 |
20150118213 | COMPOUNDS AND METHODS FOR STABILIZING THROMBIN ACTIVITY - The present invention is directed to compounds useful in stabilizing thrombin activity, thrombin compositions comprising the compounds, methods of using the compounds and methods of identifying compounds capable of stabilizing thrombin activity. The compounds are preferably isolated peptides comprising or interacting with the gamma loop of thrombin. | 2015-04-30 |
20150118214 | Pharmaceutical composition containing human cyclooxygenase and doxorubicin or doxorubicin analogue, preparation method therefor and use thereof in preparing drugs - Provided are a pharmaceutical composition containing human cyclooxygenase and doxorubicin or a doxorubicin analogue using Salvia plectranthoides (also referred to as rare grass) as a crude drug, a preparation method therefor and the use thereof in preparing drugs for treating nephritis, cholecystitis and gallbladder polyps, tumours or antiphlogistic and analgesic drugs. | 2015-04-30 |
20150118215 | Methods of Inhibiting Cell Proliferation - Described are methods of inhibiting cytohesin-2 to treat cancer, treat diabetic nephropathy, and deliver a compound into a cell. | 2015-04-30 |
20150118216 | DELIVERY OF NEGATIVELY CHARGED PROTEINS USING CATIONIC LIPIDS - Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins. | 2015-04-30 |
20150118217 | TREATMENT OF DISEASE CONDITIONS VIA ADMINISTRATION OF DNA REPAIR ENZYME - The present invention is directed to compositions and methods of preserving viability of islets of Langerhans for transplantation, and treating various disease and other abnormal or pathological conditions, including inflammatory bowel disease, ischemic heart disease, acute lung injury, acute respiratory distress syndrome and radiation-induced brain injury, with DNA repair enzymes that are directed to the mitochondria. | 2015-04-30 |
20150118218 | IMMOBILIZED PROTEIN SYSTEM FOR RAPID AND ENHANCED MULTIPLEXED DIAGNOSTICS - The disclosure relates to methods of detecting a neural injury biomarker in a biological sample. The method includes subjecting a biological sample to an assay disclosed that produces a measurable signal and detecting the measurable signal. The presence or absence of the measurable signal indicates the presence or absence of the neural injury biomarker in the sample, and thereby diagnosing a subject as having a neural injury. The disclosure further relates to methods of determining the state of a subject's neural injury. Further disclosed are systems and devices useful in carrying out the methods disclosed. | 2015-04-30 |
20150118219 | USE OF SEAPROSE TO REMOVE BACTERIAL BIOFILM - Disclosed are compositions and methods for their use in disrupting a bacterial biofilm present on a surface, comprising applying a composition that includes Seaprose to the bacterial biofilm, wherein application of the composition to the bacterial biofilm disrupts the matrix of the bacterial biofilm. | 2015-04-30 |
20150118220 | FOOD FOR NUTRITIONAL THERAPY OF AIDS - The present invention relates to food for nutritional therapy of AIDS belonging to functional foods. It is made from deep fermentation of | 2015-04-30 |
20150118221 | COMPOSITIONS AND METHODS FOR TREATING CARDIAC HYPERTROPHY - The present invention relates to the field of cardiology. More specifically, the present invention provides methods and compositions useful for treating cardiac hypertrophy. In a specific embodiment, a method for treating or preventing cardiac hypertrophy in a patient comprises the step of administering a therapeutically effective amount of a glycolipid synthesis inhibitor. | 2015-04-30 |
20150118222 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY - Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with immunotherapy are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and an immune checkpoint inhibitor. | 2015-04-30 |
20150118223 | USE OF TAU TO MONITOR IMMUNOTHERAPY - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau. | 2015-04-30 |
20150118224 | ENDOTHELIAL CELLS ACTIVATION BIOMARKERS CHARACTERIZING ANTIBODY MEDIATED REJECTION AND USES THEREOF - Described herein are methods and kits for the detection of endothelial cell injury and/or activation and to the diagnostic of transplant antibody mediated rejection (ABMR). The invention further relates to methods and kits for diagnosing endothelial to mesenchymal transition (EndMT). In various embodiments, the methods comprise assessing expression of one, two or three biomarkers selected from Fascin1, Vimentin and Hsp47. | 2015-04-30 |
20150118225 | ANTICOAGULANT ANTIDOTES - The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants. | 2015-04-30 |
20150118226 | ANTIBODIES DIRECTED AGAINST NERVE GROWTH FACTOR (NGF) - The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease. | 2015-04-30 |
20150118227 | Antibody Fc Mutants with Ablated Effector Functions - Antibody and other Fc-containing molecules with variations in the Fc region reduce binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders. | 2015-04-30 |
20150118228 | BROAD SPECTRUM ERBB LIGAND BINDING MOLECULES AND METHODS FOR THEIR USE - A chimeric ErbB ligand binding molecule is disclosed along with its pharmaceutically acceptable salt forms. The molecule is a protein that as part of its sequence includes the sequence of SEQ ID NOS: 1, 2, or 3. The molecule can be fused to an IgGFc and especially IgGFc containing cysteine to serine changes in the hinge region. For example, the fusion can be to IgG 1Fc DNA sequences that encode the binding molecules are also contemplated as well as vectors containing such DNA sequences and hosts that contain such vectors. Pharmaceutical compositions are contemplated that contain the binding molecule along with a pharmaceutically acceptable excipient. | 2015-04-30 |
20150118229 | JAK1 SELECTIVE INHIBITOR AND USES THEREOF - The invention relates to the use of a JAK1 kinase-selective inhibitor that has minimal inhibitory activity towards Jak2 kinase for treating a disease, such as an inflammatory disease (e.g., moderate to severe Rheumatoid Arthritis) and/or bone loss, either alone or in combination with a DMARD (disease modifying anti-rheumatic drug), such as methotrexate. The invention also provides pharmaceutical composition, dosage formulation, administration route, and dosage schedule thereof. | 2015-04-30 |
20150118230 | Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis - The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis. | 2015-04-30 |
20150118231 | APOE4 ANTIBODIES FOR TREATMENT OF NEURODEGENERATIVE CONDITIONS - The present invention relates to methods and compositions for treating neurodegenerative conditions, such as Alzheimer's Disease, by systemic administration of specific apoE4 antibodies. | 2015-04-30 |
20150118232 | Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent - Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same. | 2015-04-30 |
20150118233 | MONOVALENT, BIVALENT AND TRIVALENT ANTI HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) NANOBODY CONSTRUCTS FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS - Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. | 2015-04-30 |
20150118234 | SUBSTANCE SPECIFIC TO HUMAN PD-1 - The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy. | 2015-04-30 |
20150118235 | MeCP2 ISOFORM-SPECIFIC ANTIBODY FOR DETECTION OF ENDOGENOUS EXPRESSION OF MeCP2E1 - An antibody that binds a MeCP2E1 isoform of MeCP2 protein, wherein the antibody comprises a region comprising the amino acid sequence of SEQ ID NO:4. A method for detecting and/or monitoring a disease or a disorder caused by an over-expression or an under-expression of a MeCP2E1 isoform of MeCP2 protein, comprising the steps of: (i) obtaining a first sample from a mammalian subject; (ii) contacting the first sample with the anti-MeCP2E1antibody; (iii) removing unbound antibody from the sample; (iv) conducting an immunoassay on the first sample to determine a first value for expression of the MeCP2E1 isoform; (v) comparing the first value to a reference value for expression of the MeCP2E1 isoform in healthy mammalian subjects; wherein a deviation of the first value from the reference value indicates the presence of a disease or a disorder caused by an over-expression or an under-expression of the MeCP2E1 isoform. | 2015-04-30 |
20150118236 | Method for Predicting the Risk of Getting a Cardiovascular Event in a Female Subject - Subject of the present invention is a method for predicting the risk of getting a cardiovascular event in a female subject comprising determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of pro-neurotensin or fragments thereof with the a risk for getting a cardiovascular event, wherein an elevated level is predictive for an enhanced risk of getting a cardiovascular event. | 2015-04-30 |
20150118237 | ANTI-HUMAN CD69 ANTIBODY, AND USE THEREOF FOR MEDICAL PURPOSES - The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody. | 2015-04-30 |
20150118238 | Anti-c-Met Antibodies - The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to the extracellular domain of human c-Met, compositions and kits comprising such c-Met antibodies, or antigen-binding fragments thereof, and methods of using the same for detection of human c-Met that aid in identifying patients with tumors expressing or overexpressing human Met and/or improving their treatment response with anti-c-Met therapeutics. | 2015-04-30 |
20150118239 | CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST A[BETA] OLIGOMERS - The present disclosure relates to a conformational specific antibody molecule recognizing a conformational epitope of human trimeric or tetrameric oligomers, wherein said antibody molecule does not bind human monomeric Aβ 1-42 or human Ap 1-42 dimers; and pharmaceutical and diagnostic compositions comprising said antibody molecule as well as methods using same. | 2015-04-30 |
20150118240 | Anti-FcRn Antibodies - The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA. | 2015-04-30 |
20150118241 | LINGO-2 ANTAGONISTS FOR TREATMENT OF CONDITIONS INVOLVING MOTOR NEURONS - The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist. An exemplary method for promoting survival of a motor neuron, comprising contacting said motor neuron with an effective amount of a composition comprising a LINGO-2 antagonist selected from the group consisting of: (i) a soluble LINGO-2 polypeptide; (ii) a LINGO-2 antibody or antigen-binding fragment thereof; (iii) a LINGO-2 antagonist polynucleotide; (iv) a LINGO-2 aptamer; and (v) a combination of two or more of said LINGO-2 antagonists. | 2015-04-30 |
20150118242 | HEPATITIS C VIRUS NEUTRALIZING ANTIBODY - A specific epitope on the surface of the hepatitis C virus that induces a neutralizing antibody response in vivo and neutralizing monoclonal antibodies that bind specifically to the epitope are disclosed. The antibodies block hepatitis C virus from infecting cells. | 2015-04-30 |
20150118243 | Methods and Compositions for Identifying, Diagnosing, and Treating Neuroblastoma - Methods and compositions for identifying, diagnosing, and treating neuroblastoma are disclosed. | 2015-04-30 |
20150118244 | ANTI-TUMOR ANTIBODIES AS PREDICTIVE OR PROGNOSTIC BIOMARKERS OF EFFICACY AND SURVIVAL IN IPILIMUMAB-TREATED PATIENTS - Provided herein are prognostic and diagnostic methods and kits for use with the methods. For example, provided herein are methods for determining whether a subject having cancer will respond to a cancer treatment. For example, provided herein are methods for determining whether a subject having advanced melanoma will respond to a treatment with ipilimumab. Methods for determining the length of survival of cancer patients, e.g., melanoma patients, such as melanoma patients treated with ipilimumab, are also provided herein. | 2015-04-30 |
20150118245 | Predictive Biomarkers for CTLA-4 Blockade Therapy and for PD-1 Blockade Therapy - Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma. | 2015-04-30 |
20150118246 | METHOD FOR DETECTING AND CONTROLLING CANCER - Disclosed herein are: 1) methods for determining the appropriate drug therapy for a patient with colorectal cancer that has metastasized to the patient's liver and/or lung; 2) methods for treating such a patient; and 3) pharmaceutical compositions for such treatment. | 2015-04-30 |
20150118247 | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION - The invention relates to immunomodulation of cells and the detection and use thereof, for example, in drug screening, including methods, compositions and systems therefor, or in an aspect of healthcare, such as prognosis, diagnosis, an aspect of treatment, monitoring, and the like, and methods, compositions, and systems therefor. | 2015-04-30 |
20150118248 | BREAST CANCER ASSAY - The application describes a method of screening for breast cancer by testing fro the amount of HAGE (Helicase antigen) in a sample of breast tissue. Methods of prognosis of samples of breast cancer tumours are also provided. HAGE+ ER− (estrogen receptor-) cancers are indicated as being amenable to chemotherapy. Methods of treating breast cancers with HAGE-specific CTA antigen or HAGE-specific antibodies are also provided. | 2015-04-30 |
20150118249 | Stable, Aqueous Antibody Formulations - The present invention relates to stable, aqueous antibody formulations. In some embodiments, the stable, aqueous formulations comprise about 2 mg/mL to about 100 mg/mL of an anti-IL5R antibody, and about 0.002% to about 0.01% polysorbate-20. Also provided are methods of making and methods of using such antibody formulations. | 2015-04-30 |
20150118250 | MULTIVALENT RECOMBINANT AVIAN HERPES VIRUSES AND VACCINES FOR IMMUNIZING AVIAN SPECIES - The present invention relates to a recombinant | 2015-04-30 |
20150118251 | SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS - The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38 | 2015-04-30 |
20150118252 | ANTIGEN BINDING CONSTRUCTS TO CD3 - Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein. | 2015-04-30 |
20150118253 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASE USING ALPHA(2) MACROGLOBULIN-ANTIGENIC MOLECULE COMPLEXES - The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes. | 2015-04-30 |
20150118254 | ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF - The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications. | 2015-04-30 |
20150118255 | LIQUID FORMULATION OF HIGHLY CONCENTRATED LONG-ACTING HUMAN GROWTH HORMONE CONJUGATE - The present invention relates to a liquid formulation of highly concentrated long-acting human growth hormone conjugate, comprising a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent, and a method for preparing the same. | 2015-04-30 |
20150118256 | IGE CH3 Peptide Vaccine - The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine. | 2015-04-30 |
20150118257 | Methods and Compositions for Manipulating the Immune System - Methods and compositions, e.g., therapeutic agents, are provided for modulating gene and/or protein expression of Forkhead Box protein 1 (Foxp1), particularly Foxp1A and Foxp1D, in CD4+ T cells. Such modulation permits manipulation of the B cell response and antibody production and activity, without depleting the number, production or activity of the T cells. In one aspect, methods and compositions for increasing or up regulating the nucleic acid and/or protein expression of Foxp1A, Foxp1D or a combination thereof in the subject's cells in vivo, inhibits or suppresses B cell response and antibody production or activity thereof in the subject. This aspect is useful for treating diseases characterized by excessive B cell response or antibody production or activity, such as autoimmune disorders | 2015-04-30 |
20150118258 | Fluorinated Bridged Spiro[2.4]Heptane Derivatives as ALX Receptor Agonists - The present invention relates to fluorinated bridged spiro[2.4]heptane derivatives of formula (I), | 2015-04-30 |
20150118259 | 28 KDA GST PROTEINS FROM SCHISTOSOMA FOR THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AUTOIMMUNE DISEASES GENERATING A TH1 AND/OR TH17 RESPONSE - The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from | 2015-04-30 |
20150118260 | Recombinant Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4) - This invention relates to recombinant CTLA-4 proteins, e.g., soluble CTLA-4 or CTLA-4 fusion toxins, and methods for making and using them. | 2015-04-30 |
20150118261 | ESCHERICHIA COLI VACCINE COMBINATION - The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto. | 2015-04-30 |
20150118262 | Haemophilus Influenzae Type IV PILI - The invention described herein relates to a | 2015-04-30 |
20150118263 | GLYCOENGINEERED OUTER MEMBRANE VESICLES AND USE THEREOF AS VACCINES - The present application relates to glycoengineered outer membrane vesicles obtained from recombinant, gram-negaetive bacteria comprising hetereologous DNA encoding an enzyme or enzymes that produce a heterologous glycan that replaces all or a portion of the naturally-occurring O antigen in the lipopolysaccharides of the bacteria. Also provided by the present application are immunogenic compositions and vaccines prepared from the glycoengineered outer membrane vesicles expressing the heterologous glycans at their surface. | 2015-04-30 |
20150118264 | PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN - The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases. | 2015-04-30 |
20150118265 | MODIFIED ERYTHROCYTE PRECURSOR CELLS AND USES THEREOF - Provided herein are modified erythrocyte precursor cells, erythrocytes generated from modified erythrocyte precursor cells, and uses thereof. | 2015-04-30 |
20150118266 | COMPOSITION FOR PREVENTING, IMPROVING, OR TREATING IMMUNE DISEASES COMPRISING NATURAL EXTRACTS AS ACTIVE INGREDIENTS - The present invention provides a composition for preventing, improving, or treating Th1-mediated immune diseases or Th2-mediated immune diseases, an antihistamine composition, and an anti-inflammatory composition. The present invention provides a method for preventing, improving, or treating Th1-mediated immune diseases or Th2-mediated immune diseases, a method for inhibiting the release of histamine, and a method for preventing, improving, or treating inflammatory disorders. The composition according to the present invention has excellent inhibitory activities for IL-4 generation, the degranulation of mast cells, COX-2, 15-NOX, and the passing of allergens from through an intestinal epithelial cell layer, or an excellent Treg cell inducing activity. Further, the present invention provides a detailed mechanism of action of a natural substance and a food-drived antiallergenic substance, and provides stability, a reduction in production costs, and improved convenience of use by using a natural substance as a material. | 2015-04-30 |
20150118267 | METHOD OF USING THEAFLAVIN - A method for enhancing the immune system or for treating an infectious disease, the method includes administering to a subject in need thereof an effective amount of theaflavins, analogs thereof, or prodrugs thereof, or includes administering to a subject a composition comprising a physiologically acceptable carrier and an effective amount of an extract of tea. | 2015-04-30 |
20150118268 | MODULAR BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES AND USES THEREOF - A metal-organic compound containing polymer matrix includes a polymer and a three-dimensional metal-organic framework includes a polydentate organic linker. The metal-organic compound containing polymer matrix is configured to continuously produce nitric oxide when exposed to a physiological fluid including a nitric oxide-releasing compound via a catalytic reaction catalyzed by the three-dimensional metal-organic framework. | 2015-04-30 |
20150118269 | COSMETIC COMPOSITION CARRIER COMPRISING FOAMS - The present invention relates to a cosmetic composition carrier in which one or more foams having a number of pores in the range of 10 ppi to 130 ppi are impregnated with a cosmetic composition having a viscosity of 1,000 to 5,000 cps and 15,000 to 100,000 cps so as to enable a user to carry a compact type liquid cosmetic composition. | 2015-04-30 |
20150118270 | COSMETIC COMPOSITION COMPRISING MATTIFYING FILLERS AND A SILANE - The present invention relates to a composition comprising an aqueous phase, at least one mattifying filler and at least one silane corresponding to formula (I) below and/or oligomers thereof: R | 2015-04-30 |
20150118271 | PROCESS FOR MAKING A PERSONAL CARE COMPOSITION USING COMPACTED RHEOLOGY MODIFIERS - A method of making a personal care composition, such as dentifrice, using compacted rheology modifiers to control viscosity development. | 2015-04-30 |
20150118272 | METHODS FOR ENHANCING COSMETIC OR DERMATOLOGICAL NOVEL COSMETIC OR DERMATOLOGICAL COMPOSITIONS CONTAINING A DIBENZOYL METHANE DERIVATIVE BY THE ADDITION OF MODIFIED TITANIUM DIOXIDE PARTICLES - Novel cosmetic or dermatological compositions comprising multiply coated titanium dioxide particles with a water content of less than 1.5% are provided. More particularly novel cosmetic or dermatological compositions comprising multiply coated titanium dioxide particles with a water content of less than 1.5% and a dibenzoyl methane derivative are provided. | 2015-04-30 |
20150118273 | NIACINAMIDE CONTAINING COSMETIC COMPOSITIONS WITH IMPROVED SKINFEEL PROPERTIES - A cosmetic composition is provided which includes niacinamide, a carboxylic acid bearing structurant, and particles of a condensation polymerized polyamide, the polyamide having an amine value no lower than 0.3 and an HLB value of at least 16. The polyamide particles prevent interaction between niacinamide and the carboxylic acid/salt structurant thereby inhibiting skinfeel complexation and/or phase separation that would be adverse to skinfeel. | 2015-04-30 |
20150118274 | ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHOD OF USE THEREOF - A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis an a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent. | 2015-04-30 |
20150118275 | BIO-FILM RESISTANT SURFACES - The present invention relates to methods and compositions for rendering a surface resistant to bio-film formation by a combination of an alkanediol and an antimicrobial agent (and, optionally, an organic hydroxy acid). The invention provides for compositions which may be used to render surfaces bio-film resistant, articles having bio-film resistant surfaces, and methods for their preparation. The present invention may be advantageously applied to medical articles as well as articles used in non-medical contexts, such as child care or food preparation. | 2015-04-30 |
20150118276 | COATED, ANTIMICROBIAL, CHEMICALLY STRENGTHENED GLASS AND METHOD OF MAKING - The disclosure is directed to a chemically strengthened glass having antimicrobial properties and to a method of making such glass. In particular, the disclosure is directed to a chemically strengthened glass with antimicrobial properties and with a low surface energy coating on the glass that does not interfere with the antimicrobial properties of the glass. The antimicrobial has an Ag ion concentration on the surface in the range of greater than zero to 0.047 μg/cm | 2015-04-30 |
20150118277 | OXYSTEROL ANALOGUE OXY133 INDUCES OSTEOGENESIS AND HEDGEHOG SIGNALING AND INHIBITS ADIPOGENESIS - This invention relates, e.g., to a synthetic compound, Oxy133, having the structure [Formula I] or a bioactive or pharmaceutical composition comprising Oxy133 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders, including e.g. bone disorders, obesity, cardiovascular disorders, and neurological disorders. | 2015-04-30 |
20150118278 | LAMINAR CONSTRUCT FOR TISSUE-ENGINEERED DERMAL EQUIVALENT - Compositions and methods for creating a laminar construct for tissue-engineered dermal equivalent are provided. One composition provided herein comprises a hydrogel matrix comprising two or more hydrogels layers and a population of stem cells. Associated methods are also provided. | 2015-04-30 |
20150118279 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANTS AND METHODS OF USE THEREOF - Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described. | 2015-04-30 |
20150118280 | BIOACTIVE COMPOUNDS PROTECTION METHOD AND COMPOSITIONS CONTAINING THE SAME - The present invention relates to means for protecting bioactive materials in mammalian food or feed formulations used to enhance the health status of mammals. | 2015-04-30 |
20150118281 | Compositions and Methods For Modulation of Vascular Structure and/or Function - The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a β-1-4 conformation. | 2015-04-30 |
20150118282 | TRANSDERMALLY ABSORBABLE PREPARATION CONTAINING ROTIGOTINE - A method for preventing the precipitation of rotigotine crystals, including a step of mixing rotigotine and one or more crystallization prevention agents selected from the group consisting of fatty alcohols, fatty acids, fatty acid esters, fatty acid amides, and the derivatives thereof, and to a transdermally absorbable preparation that includes rotigotine and crystallization prevention agents. | 2015-04-30 |
20150118283 | Wound Dressing with an Antimicrobial Effect - The invention relates to a wound dressing which is particularly suitable for therapeutically dressing wounds. Said wound dressing comprises at least one wound covering layer and at least one sorbent based on an activated carbon which has a biocidal and/or biostatic, in particular antimicrobial effect and/or finish. | 2015-04-30 |
20150118284 | SOLID DRESSING FOR TREATING WOUNDED TISSUE - Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue. | 2015-04-30 |
20150118285 | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES - The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components. | 2015-04-30 |
20150118286 | Peptide Tyrosinase Inhibitors and Uses Thereof - Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Preferred octapeptide sequences are internally rich in tryptophan and/or tyrosine or arginine. The present invention is further directed to kits and compositions containing the present peptides, and methods of treatment of conditions involving expression of tyrosinase, in which the present peptides are administered topically for the treatment of conditions involving melanocyte activity in the skin. | 2015-04-30 |
20150118287 | SYSTEMIC DELIVERY AND REGULATED EXPRESSION OF PARACRINE GENES FOR CARDIOVASCULAR DISEASES AND OTHER CONDITIONS - In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid or gene, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid or gene in a cell or in vivo; and administering or delivering the paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to an individual or a patient in need thereof, thereby treating, ameliorating or protecting (preventing) the individual or patient against the disease, infection or condition responsive to an increased paracrine polypeptide level. | 2015-04-30 |
20150118288 | Lipid Nanoparticle Compositions and Methods of Making and Methods of Using the Same - Lipid nanoparticle formulations, methods of making, and methods of using same are disclosed. | 2015-04-30 |
20150118289 | NANOPARTICLE, METHOD OF PREPARATING THE SAME, AND USE OF THE NANOPARTICLE - A nanoparticle including a hydrophobic active ingredient and a polypeptide, as well as a liposome including the nanoparticle and methods of making and using the nanoparticle. | 2015-04-30 |
20150118290 | METHOD FOR REDUCING ESTABLISHED METASTATIC TUMOR BY PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE - A method for reducing an established metastatic tumor, comprising administering an effective amount of a pharmaceutical composition to a subject in need, wherein the pharmaceutical composition comprises a polypeptide of a fibronectin-binding domain of dipeptidyl peptidase IV having a maltose-binding protein (MBP) fused at an N-terminal thereof, a cross-linking molecule, an active agent, and a pharmaceutically acceptable carrier. | 2015-04-30 |
20150118291 | Amphoteric Liposome Formulation - The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer. | 2015-04-30 |
20150118292 | COMPOSITIONS AND METHODS FOR TREATMENT OF HAIR LOSS - The present invention is directed to compositions and methods suitable for the treatment of alopecia by topical application include minoxidil sulfate, finasteride, and 17α-estradiol. The combination is characterized by low alcohol content to minimize skin irritation and may be enhanced with the addition of vitamins, minerals, and peptides. The topical use of this combination leads to a lower overall risk of side effects than orally administered drugs. | 2015-04-30 |
20150118293 | NOVEL DELIVERY SYSTEM FOR ANTICANCER DRUG BASED ON SHORT-CHAIN-LENGTH POLYHYDROXYALKANOATE NANOPARTICLES - The invention relates to the fabrication of novel and improved delivery system comprising of short-chain-length polyhydroxyalkanoates (scl-PHA) nanoparticles having anticancer drug ellipticine (EPT) encapsulated therein for oral administration. The scl-PHA is synthesized by indigenous bacterial isolate | 2015-04-30 |
20150118294 | Triggerable Compositions For Two-Stage, Controlled Release of Proactive Chemistry - A triggerable composition for two-stage, controlled release of a functional active chemical includes a trigonelline ester of a functional active with at least one hydroxyl group configured to release the functional active through a hydrolysis reaction upon contact with an aqueous medium, and an encapsulation material for encapsulating the trigonelline ester including a functional active, the encapsulation material triggerable to release the trigonelline ester upon the occurrence of an environmental stimulus. In other aspects, a viscous liquid or an absorbent article includes a triggerable composition for two-stage, controlled release of a functional active chemical, the composition including a trigonelline ester of a functional active with at least one hydroxyl group configured to release the functional active through a hydrolysis reaction upon contact with an aqueous medium, and an encapsulation material for encapsulating the trigonelline ester including a functional active. | 2015-04-30 |